Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by N. Adlard
Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-Remitting Multiple Sclerosis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
Journal of Neurology & Neurophysiology
Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
Multiple Sclerosis International
Neurology
Pnd72 - Cost-Minimization Analysis of Teriflunomide and Dimethyl Fumarate for Treatment of Relapsing-Remitting Forms of Multiple Sclerosis in Italy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Fingolimod and CSF Neurofilament Light Chain Levels in Relapsing-Remitting Multiple Sclerosis
Neurology
Neurology
Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Chemical Health
Pharmacology
Safety
Medicine
Toxicology
Safety Research
Pharmaceutics
The Real-World Effectiveness and Safety of Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients: An Observational Study
PLoS ONE
Multidisciplinary
PND14 Budgetary Impact of the Treatment of Relapsing-Remitting Multiple Sclerosis in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
